Antiplatelet and anticoagulant therapies in acute coronary syndromes

Cardiovascular Drugs and Therapy

Volumn 24, Issue 1, 2010, Pages 61-70

  Hanna, Elias B ^a   Glancy, David Luke ^b   Saucedo, Jorge F ^a  

^a OKLAHOMA CITY UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Anticoagulant; Antiplatelet; Aspirin; Bivalirudin; Clopidogrel; Enoxaparin; Fondaparinux; Glycoprotein IIb IIIa antagonist; Myocardial infarction; Prasugrel; Ticagrelor; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; LOW DRUG DOSE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 77951295830     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6212-5     Document Type: Article

References (68)

1. W Rosamond K Flegal G Friday, et al. 2007 Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 115 e69 e171 10.1161/CIRCULATIONAHA.106.179918 17194875 (Pubitemid 46226160)
2. P Théroux H Ouimet J McCans, et al. 1988 Aspirin, heparin, or both to treat acute unstable angina N Engl J Med 319 1105 1111 3050522
3. The RISC group 1990 Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease Lancet 336 827 830
4. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 71 86
5. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study N Engl J Med 2001;345:494-502.
6. Mehta SR, Bassand JP, Chrolavicius S, et al. CURRENT-OASIS 7: a randomized, 2×2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Presented at the European Society of Cardiology Congress, Barcelona, Spain, August 2009.
7. JL Anderson CD Adams EM Antman, et al. 2007 ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction J Am Coll Cardiol 50 1 157 10.1016/j.jacc.2007.02.013 (Pubitemid 47214564)
8. SB King 3rd SC Smith Jr JW Hirshfeld Jr AK Jacobs DA Morrison DO Williams, et al. 2008 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines J Am Coll Cardiol 51 172 209 10.1016/j.jacc.2007.10.002 18191745
9. PA Gurbel RC Becker KG Mann, et al. 2007 Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 1822 1834 10.1016/j.jacc.2007.07.051 17980247 (Pubitemid 350007957)
10. TA Nguyen JG Diodati C Pharand 2005 Resistance to clopidogrel: a review of the evidence J Am Coll Cardiol 45 1157 1164 10.1016/j.jacc.2005.01.034 15837243 (Pubitemid 40523131)
11. S Yusuf F Zhao SR Mehta S Chrolavicius G Tognoni KK Fox 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 494 502 10.1056/NEJMoa010746 11519503 (Pubitemid 32758501)
12. ZM Chen LX Jiang YP Chen JX Xie HC Pan R Peto, et al. 2005 Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 1607 1621 10.1016/S0140-6736(05) 67660-X 16271642 (Pubitemid 41552416)
13. MS Sabatine CP Cannon CM Gibson JL López-Sendón G Montalescot P Theroux, et al. 2005 Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 1179 1189 10.1056/NEJMoa050522 15758000 (Pubitemid 40397259)
14. SR Steinhubl PB Berger DM Brennan EJ Topol for the CREDO Investigators 2006 Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention J Am Coll Cardiol 47 939 943 10.1016/j.jacc.2005.10.047 16516075
15. KAA Fox SR Mehta R Peters, et al. 2004 Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome. The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial Circulation 110 1202 1208 10.1161/01.CIR.0000140675.85342.1B 15313956 (Pubitemid 39202333)
16. DL Bhatt MD Flather W Hacke, et al. 2007 Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial J Am Coll Cardiol 49 1982 1988 10.1016/j.jacc.2007.03.025 17498584 (Pubitemid 46694290)
17. SR Steinhubl PB Berger JT Mann 3rd, et al. 2002 Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2411 2420 10.1001/jama.288.19.2411 12435254 (Pubitemid 35340537)
18. SR Mehta S Yusuf RJ Peters, et al. 2001 Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 527 533 10.1016/S0140-6736(01)05701-4 11520521 (Pubitemid 32772726)
19. ATL Ong EP McFadden E Regar, et al. 2005 Late angiographic stent thrombosis (LAST) events with drug-eluting stents J Am Coll Cardiol 45 2088 2092 10.1016/j.jacc.2005.02.086 15963413 (Pubitemid 40814135)
20. JS Berger CB Frye Q Harshaw FH Edwards SR Steinhubl RC Becker 2008 Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis J Am Coll Cardiol 52 1693 1701 10.1016/j.jacc.2008.08.031 19007688
21. R Ebrahimi C Dyke R Mehran, et al. 2009 Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 53 1965 1972 10.1016/j.jacc.2009.03.006 19460609
22. VL Serebruany SR Steinhubl PB Berger, et al. 2005 Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 246 251 10.1016/j.jacc.2004.09.067 15653023 (Pubitemid 40094733)
23. D Sibbing S Braun T Morath, et al. 2009 Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 849 856 10.1016/j.jacc.2008. 11.030 19264241
24. 12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose Blood Coagul Fibrinolysis 16 199 204 10.1097/01.mbc.0000164429.21040.0a
25. 12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 21 30
26. D Trenk W Hochholzer MF Fromm, et al. 2008 Cytochrome P450 2C19 polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 1925 1934 10.1016/j.jacc.2007.12.056 18482659 (Pubitemid 351636443)
27. T Simon C Verstuyft M Mary-Krause 2009 Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 363 375 10.1056/NEJMoa0808227 19106083
28. JL Mega SL Close SD Wiviott, et al. 2009 Cytochrome P-450 polymorphisms and response to clopidogrel N Engl J Med 360 354 362 10.1056/NEJMoa0809171 19106084
29. PM Ho TM Maddox L Wang, et al. 2009 Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 937 944 10.1001/jama.2009.261 19258584
30. ML O'Donoghue E Braunwald EM Antman, et al. 2009 Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 989 997 10.1016/S0140-6736(09)61525-7 19726078
31. Clopidogrel and the optimization of gastro-intestinal events trial (COGENT trial). Presented by Bhatt D at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2009), San Francisco, CA, September 24, 2009.
32. J Saw SR Steinhubl PB Berger, et al. 2003 Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 921 924 10.1161/01.CIR.0000088780.57432.43 12925453 (Pubitemid 37048218)
33. J Campo M Valgimigli D Gemmati 2007 Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to- ticlopidine crossover study J Am Coll Cardiol 50 1132 1137 10.1016/j.jacc.2007. 04.092 17868803 (Pubitemid 47375009)
34. L Bonello L Camoin-Jau S Arques, et al. 2008 Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 1404 1411
35. W Chen P Lee W Ng, et al. 2004 Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J Am Coll Cardiol 43 1122 1126 10.1016/j.jacc.2003.12.034 15028378 (Pubitemid 38353000)
36. JT Brandt CD Payne SD Wiviott, et al. 2007 A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 66.e9 66.e16 10.1016/j.ahj.2006.10.010 (Pubitemid 44895531)
37. SD Wiviott E Braunwald CH McCabe, et al. 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2001 2015 10.1056/NEJMoa0706482 17982182 (Pubitemid 350106708)
38. O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous interventionA TRITON-TIMI 38 (Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38) analysis. J Am Coll Cardiol. 2009;54:678-85.
39. SD Wiviott E Braunwald DJ Angiolillo, et al. 2008 Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Circulation 118 1626 1636 10.1161/CIRCULATIONAHA.108. 791061 18757948
40. G Montalescot SD Wiviott E Braunwald, et al. 2009 Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 723 731 10.1016/S0140-6736(09)60441-4 19249633
41. DL Bhatt 2009 Prasugrel in clinical practice N Engl J Med 361 940 942 10.1056/NEJMp0806848 19605807
42. S Husted H Emanuelsson S Heptinstall PM Sandset M Wickens G Peters 2006 Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 1038 1047 10.1093/eurheartj/ehi754 16476694
43. L Wallentin RC Becker A Budaj, et al. 2009 Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 1045 1057 10.1056/NEJMoa0904327 19717846
44. The EPISTENT Investigators 1998 Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Lancet 352 87 92
45. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35, 199730.
46. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators 1998 Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1488 1497
47. E Boersma RA Harrington DJ Moliterno, et al. 2002 Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 189 198
48. A Kastrati J Mehilli FJ Neumann, et al. 2006 Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR REACT 2 randomized trial JAMA 295 1531 1538 10.1001/jama.295.13.joc60034 16533938
49. GW Stone BT McLaurin DA Cox, et al. 2006 Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2203 2216 10.1056/NEJMoa062437 17124018 ACUITY trial (Pubitemid 44791162)
50. SG Ellis M Tendera MA de Belder, et al. 2008 Facilitated PCI in patients with ST-elevation myocardial infarction N Engl J Med 358 2205 2217 10.1056/NEJMoa0706816 18499565 (Pubitemid 351724450)
51. RP Giugliano JA White C Boden, et al. 2009 Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2176 2190 10.1056/NEJMoa0901316 19332455
52. A Oler MA Whooley J Oler D Grady 1996 Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis JAMA 276 811 815 10.1001/jama.276.10.811 8769591 (Pubitemid 26301581)
53. SG Goodman A Barr A Sobtchouk, et al. 2000 Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy J Am Coll Cardiol 36 1507 1513 10.1016/S0735-1097(00)00915-3 11079650
54. M Cohen C Demers EP Gurfinkel, et al. 1997 A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group N Engl J Med 337 447 452 10.1056/NEJM199708143370702 9250846 (Pubitemid 27333045)
55. EM Antman CH McCabe EP Gurfinkel, et al. 1999 Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Qwave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial Circulation 100 1593 1601 10517729
56. SYNERGY Trial Investigators 2004 Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 45 54 10.1001/jama.292.1.45
57. Sanderink G, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308-18.
58. GN Levine T Ferrando 2004 Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention J Thromb Thrombolysis 17 167 171 10.1023/B:THRO.0000040484.99422.77 15353913 (Pubitemid 39193982)
59. EM Antman DA Morrow CH McCabe, et al. 2006 Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354 1477 1488 10.1056/NEJMoa060898 16537665
60. E Antman M Hand PW Armstrong, et al. 2008 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 51 210 247 10.1016/j.jacc.2007.10.001 18191746
61. F Feit SV Manoukian R Ebrahimi, et al. 2008 Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol 51 1645 1652 10.1016/j.jacc.2007.11.081 18436116 (Pubitemid 351635836)
62. HD White DP Chew JW Hoekstra, et al. 2008 Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 51 1734 1741 10.1016/j.jacc.2007.12.052 18452778 (Pubitemid 351621989)
63. GW Stone B Witzenbichler G Guagliumi, et al. 2008 Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2218 2230 10.1056/NEJMoa0708191 18499566 (Pubitemid 351724451)
64. R Mehran AJ Lansky B Witzenbichler, et al. 2009 Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 1149 1159 10.1016/S0140-6736(09)61484-7 19717185
65. S Yusuf SR Mehta S Chrolavicius, et al. 2006 Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 1464 1476 10.1056/NEJMoa055443 16537663 OASIS 5 trial
66. SR Mehta WE Boden JW Eikelboom, et al. 2008 Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the fifth and sixth organization to assess strategies in ischemic syndromes (OASIS 5 and 6) randomized trials Circulation 118 2038 2046 10.1161/CIRCULATIONAHA.108.789479 18955665
67. The OASIS-6 Trial Group 2006 Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 1519 1530 10.1001/jama.295.13.joc60038
68. KA Fox EM Antman G Montalescot, et al. 2007 The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial J Am Coll Cardiol 49 2249 2255 10.1016/j.jacc.2006.12.049 17560289 (Pubitemid 46863477)